UPDATE: Jefferies Reiterates Buy, Ups PT to $33 on ViroPharma

Jefferies maintains its Buy rating on ViroPharma VPHM as new Vancocin strategy is risky but may be worth up to $6/share. Jefferies says, “VPHM announced the surprise approval of a new label for Vancocin, which they believe will provide 3 years of protection from a generic launch. Applying a 75% probability of success, this raises our price target from $28 to $33. Based on our initial diligence, the key risk is convincing the FDA that a generic Vancocin label without the new data is less “safe and effective.” VPHM closed at $27.80 per share on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetPre-Market OutlookAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!